Hui-Qiang Huang

Prof. Dr. Hui-Qiang Huang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in OncoImmunology
Verified
Journal Article
Open access
HHHai-Xia He
Hai-Xia He
YGYan Gao
Yan Gao
JFJian-Chang Fu
Jian-Chang Fu
QZQiang-Hua Zhou
Qiang-Hua Zhou
XWXiao-Xiao Wang
Xiao-Xiao Wang
HHHui-Qiang Huang
Hui-Qiang Huang
Although PD-1/PD-L1 blockade therapy confers salutary effects across cancer types, their efficacy in Extranodal Natural killer/T-cell lymphoma (ENKTCL) patients is limited and unpredictable. Here, we comprehensively evaluated the expression profile of a panel of immune-regulatory makers to identify novel prognostic biomarkers and/or therapeutic targets for this malignancy. Using immunohistochemistry and multiplex immunofluorescence, we found that the expression of VISTA (88.1%) was predominantly in CD68+ macrophages and much higher than PD-L1 expression (68.7%) in ENKTCL. B7-H4 and HHLA2 proteins were not detected in ENKTCL. B7-H3 was expressed in minority of ENKTCL patients (13.7%) and mainly colocalized with CD31. A close correlation was detected between VISTA and PD-L1, but they were not co-expressed in the same cells. High expressions of VISTA or PD-L1 were significantly associated with detrimental clinicopathological characteristics, dismal prognosis, and high density of CD8+ TILs, and high VISTA expression was also significantly associated with high density of Foxp3+ TILs. VISTA combined with PD-L1 was an independent prognostic factor for PFS and OS. Moreover, the patients with high VISTA showed a poor response to PD-1 blockades in ENKTCL. In conclusion, these findings provide a rationale for VISTA as an ideal immunotherapeutic target next to PD-L1 for ENKTCL.

14 June 2019 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
ZLZ.-X. Lin
Z.-X. Lin
DRD.-Y. Ruan
D.-Y. Ruan
CJC.-C. Jia
C.-C. Jia
TWT.-T. Wang
T.-T. Wang
JCJ.-T. Cheng
J.-T. Cheng
XWXiang-Yuan Wu
Xiang-Yuan Wu

15 January 2019 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
XWXiao-Xiao Wang
Xiao-Xiao Wang
PLPeng-Fei Li
Peng-Fei Li
BBBing Bai
Bing Bai
YGYan Gao
Yan Gao
QRQi-Xiang Rong
Qi-Xiang Rong
HHHui-Qiang Huang
Hui-Qiang Huang
Circulating EBV-DNA is an accurate biomarker of tumor load in extranodal natural killer (NK)/T cell lymphoma (ENKTL); however, its role in patients treated with P-GEMOX has not been evaluated. In this study, we examined plasma EBV-DNA of 99 patients at different time points by real-time quantitative polymerase chain reaction. Multivariate analysis revealed that ECOG PS score, response rate, and post-treatment EBV-DNA level were independent predictors of progression-free survival (PFS) and overall survival (OS). Positive post-treatment plasma EBV-DNA was associated with poor OS in ENKTL patients. The 3-year OS for patients with positive pre-, interim-, post-treatment EBV-DNA was significantly lower than that for patients with negative EBV-DNA; the values were 70.2% vs. 93.9% (p = .022), 53.8% vs. 99.1% (p < .001), and 40.6% vs. 91.8% (p < .001), respectively. We conclude that monitoring dynamic changes in plasma EBV-DNA in ENKTL patients treated with P-GEMOX could predict important outcomes such as OS.

9 July 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YHYanxia He
Yanxia He
YGYan Gao
Yan Gao
LPLiqin Ping
Liqin Ping
HHHaixia He
Haixia He
CHCheng Huang
Cheng Huang
HHHui-Qiang Huang
Hui-Qiang Huang

4 December 2020 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
BBBing Bai
Bing Bai
XWXiao-Xiao Wang
Xiao-Xiao Wang
YGYan Gao
Yan Gao
PLPeng-Fei Li
Peng-Fei Li
HHHai-Xia He
Hai-Xia He
HHHui-Qiang Huang
Hui-Qiang Huang

16 August 2018 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
PLPeng-Fei Li
Peng-Fei Li
YMYi-Ze Mao
Yi-Ze Mao
BBBing Bai
Bing Bai
YGYan Gao
Yan Gao
YZYu-Jing Zhang
Yu-Jing Zhang
HHHui-Qiang Huang
Hui-Qiang Huang